Literature DB >> 21631587

Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.

Fabien Lamoureux1, Nicolas Picard, Belkacem Boussera, François-Ludovic Sauvage, Pierre Marquet.   

Abstract

The mTOR inhibitors (ImTORs) sirolimus (SRL) and everolimus (EVR) have been increasingly used in renal transplantation as part of calcineurin inhibitor (CNI) sparing or avoidance regimens. Those drugs have low and variable oral bioavailability that is increased when combined with cyclosporine or tacrolimus (TAC). We investigated the mechanisms involved in ImTORs intestinal absorption in vitro and associated it with their drug-drug interactions with CNIs. The transport of ImTORs across Caco-2 cells was studied in the apical (A) to basolateral (B) and B to A directions, in the absence or presence of cyclosporine, TAC, and GF120918 (P-gp inhibitor). In Caco-2 cells, EVR and SRL displayed a polarized transport with 8.7- and 5.9-fold higher P(app,B→A) than P(app,A→B), respectively. P-gp inhibition by GF120918 resulted in a 70 and 41% decrease in EVR and SRL efflux, respectively. Cyclosporine and TAC led to a comparable and significant decrease in the efflux ratio of ImTORs, suggesting inhibition of a P-gp-mediated efflux transport. Cyclosporine also exhibited a specific increase of P(app,B→A), which may be attributed to the inhibition of other transporters and/or metabolizing enzymes. In conclusion, EVR and SRL are both subject to an apically directed efflux mediated by P-gp. TAC mainly inhibits this efflux mechanism, while the effect of cyclosporine appears to be more complex with mechanisms to be confirmed by further studies.
© 2011 The Authors Fundamental and Clinical Pharmacology © 2011 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21631587     DOI: 10.1111/j.1472-8206.2011.00957.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  6 in total

1.  Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis.

Authors:  Manon Launay; Antoine Roux; Laurence Beaumont; Benoit Douvry; Lucien Lecuyer; Emmanuel Douez; Clément Picard; Dominique Grenet; Vincent Jullien; Véronique Boussaud; Romain Guillemain; Eliane M Billaud
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 2.  Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.

Authors:  Marie Lund; Tonny Studsgaard Petersen; Kim Peder Dalhoff
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

3.  mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation.

Authors:  Roberto Gedaly; Felice De Stefano; Lilia Turcios; Marita Hill; Giovanna Hidalgo; Mihail I Mitov; Michael C Alstott; D Allan Butterfield; Hunter C Mitchell; Jeremy Hart; Ahmad Al-Attar; Chester D Jennings; Francesc Marti
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

4.  Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer.

Authors:  K Wu; E E W Cohen; L K House; J Ramírez; W Zhang; M J Ratain; R R Bies
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-12-05

5.  Flucloxacillin decreases tacrolimus blood trough levels: a single-center retrospective cohort study.

Authors:  Herman Veenhof; Hugo M Schouw; Martine T P Besouw; Daan J Touw; Valentina Gracchi
Journal:  Eur J Clin Pharmacol       Date:  2020-07-25       Impact factor: 2.953

Review 6.  The Effects of Bariatric Surgery and Gastrectomy on the Absorption of Drugs, Vitamins, and Mineral Elements.

Authors:  Miłosz Miedziaszczyk; Patrycja Ciabach; Edyta Szałek
Journal:  Pharmaceutics       Date:  2021-12-07       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.